BreakVax (BB-101)
/ BreakBio Corp
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 14, 2026
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
(clinicaltrials.gov)
- P1/2 | N=10 | Not yet recruiting | Sponsor: BreakBio Corp
New P1/2 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor
August 13, 2026
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
(clinicaltrials.gov)
- P1/2 | N=10 | Not yet recruiting | Sponsor: BreakBio Corp
New P1/2 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PD-L1
1 to 2
Of
2
Go to page
1